New Release: A Joint Consensus Statement by IOCN & British Cardio-Oncology Society – Baseline Cardiac Assessment
The Immuno-Oncology Clinical Network (IOCN) and the British Cardio-Oncology Society (BCOS) are proud to announce the publication of their first joint consensus statement:
“Baseline Cardiac Assessment in Individuals Receiving Immune Checkpoint Inhibitors: A Joint Consensus Statement.”
This ground-breaking statement provides critical guidance on cardiac evaluations for patients receiving immune checkpoint inhibitors (ICIs), ensuring optimal care and minimising risks associated with cardiotoxicities.
Key highlights of the consensus statement include:
-The importance of baseline cardiac assessments (biochemical and cardiac imaging assessments).
-Practical recommendations for interdisciplinary management of ICI-related cardiac risks.
-Guidance on early detection and monitoring strategies for healthcare professionals
Why This Matters:
Immune checkpoint inhibitors have transformed cancer care, but their potential to cause immune-mediated cardiovascular side effects presents unique challenges.
This consensus statement aims to guide oncologists and cardiologists in implementing baseline cardiac assessments for patients initiating ICIs, bridging the gap between oncology and cardiology, offering a unified approach to improving patient outcomes.
It provides actionable recommendations for interpreting results without delaying cancer treatment whilst ensuring recommendations are feasible for diverse healthcare settings in the UK.
Access the Statement:
The consensus statement is now available on the IOCN website: https://ioclinicalnetwork.co.uk/clinical-support/iocn-consensus-statements
The IOCN and BCOS are committed to supporting healthcare professionals in navigating the complexities of immune checkpoint inhibitor therapy. We believe this consensus statement is a significant step forward in ensuring the safety and well-being of patients undergoing these life-changing treatments. We invite you to explore the full statement and join us in advancing collaborative care practices that prioritise patient outcomes. Together, we can bridge the gap between oncology and cardiology to meet the evolving needs of cancer care.
For further information or to learn more about our initiatives, please visit our website or reach out to us directly.
Kind Regards,
Dr Anna-Olsson Brown
CEO of the Immuno-Oncology Clinical Network
